RBC Capital Reiterates Outperform Rating on Legend Biotech Corporation (LEGN)

Market Context

Legend Biotech Corporation operates in the Healthcare sector. The stock currently trades at $19.27 with a market capitalization of $2.1B. The stock has declined 49.9% over the past 52 weeks.

Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Legend Biotech Corporation.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Legend Biotech Corporation

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 28, 2026	HC Wainwright & Co.	Buy	N/A
Jul 27, 2026	RBC Capital	Outperform	N/A
Jul 24, 2026	UBS	Neutral	N/A
Jul 13, 2026	JP Morgan	Neutral	N/A
Jul 07, 2026	RBC Capital	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View LEGN Stock Page